SS Innovations International Inc. (NASDAQ: SSII) has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, an independent industry endorsement that underscores the company’s growing presence in the rapidly expanding global surgical robotics market. The recognition comes as the company’s flagship SSi Mantra surgical robotic system continues to gain traction, with more than 11,700 procedures completed globally and regulatory approvals secured in 14 countries.
The award was presented after SS Innovations was selected from a field of ten finalists that included established medical technology companies such as Intuitive, Johnson & Johnson MedTech, Medtronic, and others (https://nnw.fm/mXdgs). The Surgical Robotics Industry Awards evaluate companies based on commercial performance, technological innovation, societal impact, customer recognition, ethical standards, and workplace practices.
Dr. Sudhir Srivastava, Chairman and Chief Executive Officer of SS Innovations, stated that the award reflects the company’s commitment to expanding access to robotic surgery while developing technologies that improve affordability for hospitals and healthcare systems. This focus has driven the company’s operational growth, with surgeons completing a cumulative 11,719 multi-specialty procedures using the SSi Mantra system as of June 22, 2026. These procedures include 612 cardiac surgeries, 175 telesurgeries, and 212 pediatric operations, demonstrating the platform’s versatility across multiple surgical disciplines.
The breadth of clinical adoption is further highlighted by the fact that physicians have used the SSi Mantra in more than 170 different types of surgical procedures. Training has expanded in tandem, with approximately 2,100 physicians now trained on the platform. Physician education and clinical familiarity are critical factors that often influence hospital purchasing decisions and long-term utilization of robotic surgery systems.
Internationally, SS Innovations has obtained regulatory approvals in 14 countries: Colombia, Ecuador, Guatemala, Guyana, India, Indonesia, Iraq, Kenya, Nepal, Oman, the Philippines, Sri Lanka, Ukraine, and the United Arab Emirates. These approvals provide opportunities for continued market expansion as healthcare systems globally evaluate robotic-assisted surgery for a broader range of procedures.
The SSi Mantra is a modular, multi-arm robotic surgery platform designed to support multiple surgical specialties. It features between three and five robotic arms, a three-dimensional 4K visualization system, an ergonomic surgeon console, and digital imaging capabilities that allow integration of diagnostic information during procedures. The instrument portfolio includes more than 40 robotic surgical instruments, including smaller 5-millimeter instruments intended for pediatric and ear, nose, and throat procedures.
The company has also developed a portable tele-surgeon console, known as the SSi MantrAsana, which supports remote surgical capabilities. While telesurgery remains an emerging area of robotic medicine, SS Innovations has reported performing more than 20 cardiac telesurgeries using the platform.
For more information, visit the company’s website at www.SSInnovations.com.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SS Innovations Wins Outstanding Company at 2026 Surgical Robotics Industry Awards.